Healthcare Industry News: blood glucose monitoring
News Release - January 6, 2010
T2 BioSystems Appoints Ken Toso Vice President, Product DevelopmentCompany Preparing for Commercial Evaluation and Launch
CAMBRIDGE, Mass.--(HSMN NewsFeed)--T2 Biosystems, Inc., a company developing the first point-of-care medical diagnostic products that enable rapid molecular and immunodiagnostic testing on a single instrument, today announced it has appointed Ken Toso as Vice President, Product Development. This appointment and creation of a new position reflects the Company’s progress in developing its technology for commercial utility as it moves from an alpha instrument completed in 2009 to beta instrument development during 2010.
T2 Biosystems is developing the next generation of medical diagnostic products through its proprietary technology, which combines nanotechnology and the miniaturization of proven MR technology. T2 Biosystems’ magnetic resonance-based diagnostics are poised to offer improved speed, accuracy and efficiency, as well as portability to a broader range of settings including doctor’s offices, homes and hospitals.
Mr. Toso brings to T2 BioSystems more than 25 years of industry experience in medical device technologies, spanning product research, development and manufacturing. His innovative product experiences and launches have spanned multiple clinical areas within the fields of in vitro diagnostics and medical devices, including General Surgery, Gynecology, Urology, Cardiology, Oncology and blood glucose monitoring.
“We are delighted to welcome Ken to our leadership team as his expertise will be invaluable as we advance our technology towards the marketplace,” said John McDonough, CEO of T2 Biosystems. “Ken is joining T2 at a critical time of our growth and evolution to a commercial- stage company.”
Most recently, Mr. Toso served as Sr. Vice President of Engineering at Grove Instruments and as Vice President of Research and Development for the Oncology division of Boston Scientific where he directed the launch of eight new products in one year’s time. Prior to Boston Scientific, Mr. Toso served as VP of R&D for ACMI Circon and had directed the launch of 22 new products within his 3-year tenure. Mr. Toso also served as Vice President of Engineering at Xylum and started his career at US Surgical, where he served in a variety of technical and management roles, directing the launch of more than 35 new products. Mr. Toso earned his Bachelor’s degree in Mechanical Engineering from SUNY at Stony Brook and M.B.A. from the University of Bridgeport and holds more than 20 US granted patents.
T2 Biosystems’ technology has been validated in multiple published journal articles and has shown to accurately analyze viruses, bacteria, proteins, hormones, DNA, small molecules and other diagnostic targets. The Company is developing a pipeline of diagnostic products based on its technology, including devices for hospitals, diagnostic laboratories and medical offices, as well as individual patients.
About T2 Biosystems
T2 Biosystems is a private biotechnology company developing next-generation medical diagnostic products using its proprietary technology, combining nanotechnology and miniaturized magnetic resonance (MR) technology to provide rapid, accurate and portable diagnostics. T2 Biosystems was founded in 2006 by renowned researchers from the Massachusetts Institute of Technology, Harvard University, Harvard Medical School and Massachusetts General Hospital, and has assembled a world-class team, board of directors and scientific advisory board that collectively have a proven track record of translating technologic innovations into breakthrough products, building significant corporate value. T2 Biosystems is located in Cambridge, Massachusetts. For more information, please visit the company's website at www.t2biosystems.com.
Source: T2 Biosystems
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.